SIETES :: 93213 citas

Resultados de la búsqueda por PROTEÍNA C REACTIVA REFINAR BÚSQUEDA

1.

Torres A, Sibila O, Ferrer M, Polverino E, Menéndez R, Mensa J, Gabarrús A, Sellarés J, Restrepo MI, Anzueto A, Niederman MS, Agustí C. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 2015;313:677-86. [Ref.ID 98813]

2.

Wunderink RG. Corticosteroids for severe community-acquired pneumonia: not for everyone. JAMA 2015;313:673-4. [Ref.ID 98812]

3.

Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012;380:565-71. [Ref.ID 93575]

4.

Tzoulaki I, Siontis KCM, Ioannidis JPA. Prognostic effect size of cardiovascular biomarkers in datasets from observational studies versus randomised trials: meta-epidemiology study. BMJ 2011;343:1137. [Ref.ID 91919]

5.

Anónimo. Why do the results of randomised and observational studies differ?. BMJ 2011;343:1128. [Ref.ID 91915]

6.

Emberson J, Bennett D, Parish S, Armitage J, Collins R, on behalf of the Heart Protection Study Collaborative Group. C-reactive protein in the Heart Protection Study. Authors' reply. Lancet 2011;377:1918-9. [Ref.ID 91291]

7.

Ridker PM, Koenig W, Kastelein JJP. C-reactive protein in the Heart Protection Study. Lancet 2011;377:1918. [Ref.ID 91290]

8.

C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC). Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ 2011;342:425. [Ref.ID 90228]

9.

Keavney B. C reactive protein and the risk of cardiovascular disease. BMJ 2011;342:393-4. [Ref.ID 90224]

10.

Heart Protection Study Collaborative Group. C-reactive protein concentration and the vascular benefits of statin therapy. an analysis of 20 536 patients in the Heart Protection Study. Lancet 2011;377:469-76. [Ref.ID 90201]

11.

Després J-P. CRP: star trekking the galaxy of risk markers. Lancet 2011;377:441-2. [Ref.ID 90199]

12.

Ridker PM, Genest J, Boekholdt SM, Libby P, Gotto AM, Nordestgaard BG, Mora S, MacFadyen JG, Glynn RJ, Kastelein JJP, for the JUPITER Trial Study Group. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet 2010;376:333-9. [Ref.ID 89009]

13.

Hausenloy DJ, Opie L, Yellon DM. Dissociating HDL cholesterol from cardiovascular risk. Lancet 2010;376:305-6. [Ref.ID 89001]

14.

Anónimo. Rosuvastatina (Crestor) y riesgo de diabetes. PAM 2010;34:440-1. [Ref.ID 88966]

15.

Ridker PM, Glynn RJ. JUPITER, rosuvastatin, and the European Medicines Agency. Lancet 2010;375:2071. [Ref.ID 88667]

16.

Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med 2010;152:488-96. [Ref.ID 88328]

17.

Habersberger J, Eisenhardt S, Peter K. C-reactive protein measurement and cardiovascular disease. Lancet 2010;375:1078. [Ref.ID 88176]

18.

Boekholdt SM, Kastelein JJ. C-reactive protein measurement and cardiovascular disease. Authors' reply. Lancet 2010;375:1077-8. [Ref.ID 88175]

19.

Wald DS, Bestwick JP. C-reactive protein measurement and cardiovascular disease. Lancet 2010;375:1077. [Ref.ID 88174]

20.

The Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010;375:132-40. [Ref.ID 87558]